Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2022-02-06
Target enrollment:
Participant gender:
Summary
This multicenter, open label, single-arm study is aim at investigating the the efficacy and
safety of china made ambrisentan in Chinese subjects with PAH.
Phase:
Phase 3
Details
Lead Sponsor:
RenJi Hospital
Collaborators:
First Affiliated Hospital of Chongqing Medical University Shanghai Pulmonary Hospital, Shanghai, China Shanghai Zhongshan Hospital The Affiliated Hospital of Qingdao University The First Affiliated Hospital with Nanjing Medical University Wuhan Asia Heart Hospital Xinqiao Hospital of Chongqing